OptiBiotix signs commercialisation agreement with Nutralinea

Obesity, high cholesterol, diabetes and skin care-focussed life sciences business OptiBiotix Health announced on Tuesday that it agreed to grant a non-exclusive license agreement to Nutrilinea for the production and commercialisation of products containing OptiBiotix's LPLDL strain in Europe with a view to maximising the financial return for both parties.

The AIM-traded firm said Nutrilinea had more than 15 years of experience in the design and development of customised formulations and presentations, including capsules, tablets and sachets, for the supplement and pharmaceutical industry.

It said Nutrilinea provided products to both national and international businesses in Europe and the US, and was one of Europe's fastest growing providers of food supplements, doubling revenues in the last 12 months to over €30m per annum.

It is based in Italy and had established an international reputation for providing innovative product formulations and presentations for different markets, including products containing some of the world's best selling probiotic strains, OptiBiotix claimed.

Nutrilinea intended to produce proprietary formulations containing OptiBiotix's LPLDL strain developed to reduce cholesterol levels and blood pressure - CholBiome - and cardiovascular risk - CardioBiome.

Under the terms of the agreement, Nutrilinea intended to produce, promote, market and commercialise OptiBiotix's CholBiome and CardioBiome products to their European network with the aim of maximising the financial return for both parties, the OptiBiotix board reported.

It said the pre-launch agreement was another step in a business to business strategy of bringing OptiBiotix's science together with partner's expertise and market reach to serve multiple consumer healthcare and pharmaceutical markets around the world.

“We are pleased to announce this non-exclusive license agreement with Nutrilinea for the production and commercialisation of products containing OptiBiotix's LPLDL strain for the reduction of cholesterol and cardiovascular risk,” said CEO Stephen O'Hara.

“We chose Nutrilinea due to its industry reputation, extensive European network, and record of doubling revenues in the last 12 months.”

O’Hara said the OptiBiotix board believed that working with Nutrilinea, and similar partners around the world, provided the “best opportunity” to build LPLDL into a global brand.

“We see this as another step in building revenues and market presence of LPLDL as the 'Intel' inside a wide range of products, provided in different presentations and formulations, for cardiovascular health across both consumer and pharmaceutical markets around the world.”